{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:05:46Z","timestamp":1792785946349,"version":"4.5.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Center for HIV\/AIDS"},{"name":"Viral Hepatitis, STD and TB Prevention"},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["5U38PS004646"],"award-info":[{"award-number":["5U38PS004646"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["5U38PS004650"],"award-info":[{"award-number":["5U38PS004650"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although effective against hepatitis B virus (HBV) infection, hepatitis B (HepB) vaccination is only recommended for infants, children, and adults at higher risk. We conducted an economic evaluation of universal HepB vaccination among US adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a decision analytic model with Markov disease progression, we compared current vaccination recommendations (baseline) with either 3-dose or 2-dose universal HepB vaccination (intervention strategies). In simulated modeling of 1 million adults distributed by age and risk groups, we quantified health benefits (quality-adjusted life years, QALYs) and costs for each strategy. Multivariable probabilistic sensitivity analyses identified key inputs. All costs reported in 2019 US dollars.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>With incremental base-case vaccination coverage up to 50% among persons at lower risk and 0% increment among persons at higher risk, each of 2 intervention strategies averted nearly one-quarter of acute HBV infections (3-dose strategy, 24.8%; 2-dose strategy, 24.6%). Societal incremental cost per QALY gained of $152\u00a0722 (interquartile range, $119\u00a0113\u2013$235\u00a0086) and $155\u00a0429 (interquartile range, $120\u00a0302\u2013$242\u00a0226) were estimated for 3-dose and 2-dose strategies, respectively. Risk of acute HBV infection showed the strongest influence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Universal adult vaccination against HBV may be an appropriate strategy for reducing HBV incidence and improving resulting health outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiac088","type":"journal-article","created":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T07:07:59Z","timestamp":1646464079000},"page":"1041-1051","source":"Crossref","is-referenced-by-count":16,"title":["Assessing the Cost-Utility of Universal Hepatitis B Vaccination Among Adults"],"prefix":"10.1093","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0244-7458","authenticated-orcid":false,"given":"Eric W","family":"Hall","sequence":"first","affiliation":[{"name":"School of Public Health, Oregon Health and Science University , Portland, Oregon , USA"},{"name":"Emory University, Rollins School of Public Health, Department of Epidemiology , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark K","family":"Weng","sequence":"additional","affiliation":[{"name":"National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M","family":"Harris","sequence":"additional","affiliation":[{"name":"National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Schillie","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noele P","family":"Nelson","sequence":"additional","affiliation":[{"name":"National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael R","family":"Ortega-Sanchez","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, University at Albany , Rensselaer, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick S","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Emory University, Rollins School of Public Health, Department of Epidemiology , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Lopman","sequence":"additional","affiliation":[{"name":"Emory University, Rollins School of Public Health, Department of Epidemiology , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9165-1658","authenticated-orcid":false,"given":"Jeb","family":"Jones","sequence":"additional","affiliation":[{"name":"Emory University, Rollins School of Public Health, Department of Epidemiology , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Bradley","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Georgia State University , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli S","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, University at Albany , Rensselaer, New York , USA"},{"name":"New York State Department of Health , Albany, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"2022092122004656100_CIT0001","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.28109","article-title":"Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988\u20132012.","volume":"63","author":"Roberts","year":"2016","journal-title":"Hepatology"},{"key":"2022092122004656100_CIT0002","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/hep.31782","article-title":"An updated assessment of chronic hepatitis B prevalence among foreign-born persons living in the United States.","volume":"74","author":"Wong","year":"2021","journal-title":"Hepatology"},{"key":"2022092122004656100_CIT0003","volume-title":"Viral Hepatitis Surveillance, United States, 2018: Division of Viral Hepatitis","author":"Centers","year":"2020"},{"key":"2022092122004656100_CIT0004","first-page":"317","article-title":"Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine.","volume":"31","author":"Centers for Disease Control","year":"1982","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022092122004656100_CIT0005","first-page":"1","article-title":"A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part 1: immunization of infants, children, and adolescents.","volume":"54","author":"Mast","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"2022092122004656100_CIT0006","first-page":"1","article-title":"A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part II: immunization of adults.","volume":"55","author":"Mast","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"2022092122004656100_CIT0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","article-title":"Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices.","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Recomm Rep"},{"key":"2022092122004656100_CIT0008","doi-asserted-by":"crossref","first-page":"784","DOI":"10.15585\/mmwr.mm6429a3","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years\u2014United States, 2014.","volume":"64","author":"Reagan-Steiner","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022092122004656100_CIT0009","volume-title":"Vaccination coverage among adults in the United States, national health interview survey, 2016.","author":"Hung","year":"2018"},{"key":"2022092122004656100_CIT0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","article-title":"Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014.","volume":"108","author":"Zibbell","year":"2018","journal-title":"Am J Public Health"},{"key":"2022092122004656100_CIT0011","volume-title":"Eliminating the public health problem of hepatitis B and C in the United States: Phase one report","author":"Committee on a National Strategy for the Elimination of Hepatitis B and C; Board on Population Health and Public Health Practice; Health and Medicine Division; National Academies of Sciences Engineering, and Medicine.","year":"2016"},{"key":"2022092122004656100_CIT0012","volume-title":"Annual estimates of the resident population by single year of age and sex for the United States: April 1, 2010 to July 1, 2017","author":"US Census Bureau.","year":"2018"},{"key":"2022092122004656100_CIT0013","volume-title":"Viral hepatitis surveillance, United States, 2017: Division of Viral Hepatitis,","author":"Centers for Disease Control and Prevention.","year":"2019"},{"key":"2022092122004656100_CIT0014","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/cid\/ciz001","article-title":"Prevalence of hepatitis B and hepatitis D virus infections in the United States, 2011\u20132016.","volume":"69","author":"Patel","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022092122004656100_CIT0015","doi-asserted-by":"crossref","first-page":"794","DOI":"10.7326\/M17-1106","article-title":"Hepatitis B vaccination, screening, and linkage to care: best practice advice from the American College of Physicians and the Centers for Disease Control and Prevention.","volume":"167","author":"Abara","year":"2017","journal-title":"Ann Intern Med"},{"key":"2022092122004656100_CIT0016","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/jvh.13060","article-title":"Awareness of chronic viral hepatitis in the United States: an update from the National Health and Nutrition Examination Survey.","volume":"26","author":"Kim","year":"2019","journal-title":"J Viral Hepat"},{"key":"2022092122004656100_CIT0017","doi-asserted-by":"crossref","first-page":"718","DOI":"10.15585\/mmwr.mm6833a2","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317 years\u2014United States, 2018.","volume":"68","author":"Walker","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022092122004656100_CIT0018","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1016\/j.vaccine.2013.06.041","article-title":"Self-report compared to electronic medical record across eight adult vaccines: do results vary by demographic factors?","volume":"31","author":"Rolnick","year":"2013","journal-title":"Vaccine"},{"key":"2022092122004656100_CIT0019","doi-asserted-by":"crossref","first-page":"S389","DOI":"10.2105\/AJPH.2008.151332","article-title":"Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study.","volume":"99","author":"Nelson","year":"2009","journal-title":"Am J Public Health"},{"key":"2022092122004656100_CIT0020","volume-title":"TWINRIX prescribing information","author":"Glaxo Smith Kline.","year":"2018"},{"key":"2022092122004656100_CIT0021","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.4161\/hv.7.12.18333","article-title":"Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults \u226550 years.","volume":"7","author":"Gilbert","year":"2011","journal-title":"Hum Vaccin"},{"key":"2022092122004656100_CIT0022","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.vaccine.2012.01.087","article-title":"Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18\u201355 years of age.","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"2022092122004656100_CIT0023","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.vaccine.2017.12.038","article-title":"Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"key":"2022092122004656100_CIT0024","author":"Centers for Disease Control and Prevention."},{"key":"2022092122004656100_CIT0025","volume-title":"Consumer price index for all urban consumers (CPI-U): US city average, by expenditure category, January 2019,","author":"Bureau of Labor Statistics.","year":"2019"},{"key":"2022092122004656100_CIT0026","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.amepre.2019.03.011","article-title":"Insurance reimbursements for routinely recommended adult vaccines in the private sector.","volume":"57","author":"Tsai","year":"2019","journal-title":"Am J Prev Med"},{"key":"2022092122004656100_CIT0027","volume-title":"Clinical diagnostic laboratory fee (CLAB)","author":"Center for Medicare and Medicaid Services.","year":"2021"},{"key":"2022092122004656100_CIT0028","author":"Bureau"},{"key":"2022092122004656100_CIT0029","author":"TreeAge"},{"key":"2022092122004656100_CIT0030","first-page":"1","article-title":"United States life tables, 2015.","volume":"67","author":"Arias","year":"2018","journal-title":"Natl Vital Stat Rep"},{"key":"2022092122004656100_CIT0031","doi-asserted-by":"crossref","first-page":"ofy353","DOI":"10.1093\/ofid\/ofy353","article-title":"Cost-effectiveness of hepatitis B virus infection screening and treatment or vaccination in 6 high-risk populations in the United States.","volume":"6","author":"Chahal","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2022092122004656100_CIT0032","doi-asserted-by":"crossref","first-page":"8206","DOI":"10.1016\/j.vaccine.2020.10.067","article-title":"Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations.","volume":"38","author":"Rosenthal","year":"2020","journal-title":"Vaccine"},{"key":"2022092122004656100_CIT0033","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.vaccine.2012.11.097","article-title":"Number-needed-to-vaccinate calculations: fallacies associated with exclusion of transmission.","volume":"31","author":"Tuite","year":"2013","journal-title":"Vaccine"},{"key":"2022092122004656100_CIT0034","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2105\/AJPH.2013.301601","article-title":"Estimating acute viral hepatitis infections from nationally reported cases.","volume":"104","author":"Klevens","year":"2014","journal-title":"Am J Public Health"},{"key":"2022092122004656100_CIT0035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/infdis\/jiw142","article-title":"A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B virus (HBV) cellular immunity despite loss of antibody against HBV surface antigen.","volume":"214","author":"Simons","year":"2016","journal-title":"J Infect Dis"},{"key":"2022092122004656100_CIT0036","doi-asserted-by":"crossref","first-page":"455","DOI":"10.15585\/mmwr.mm6715a5","article-title":"Recommendations of the advisory committee on immunization practices for use of a hepatitis B vaccine with a novel adjuvant.","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022092122004656100_CIT0037","doi-asserted-by":"crossref","DOI":"10.1093\/acprof:oso\/9780190492939.001.0001","volume-title":"Cost-effectiveness in health and medicine","author":"Neumann","year":"2016"},{"key":"2022092122004656100_CIT0038","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40273-020-00942-2","article-title":"Perspective and costing in cost-effectiveness analysis, 1974\u20132018.","volume":"38","author":"Kim","year":"2020","journal-title":"PharmacoEcon"},{"key":"2022092122004656100_CIT0039","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/bmb\/ldq033","article-title":"Health outcomes in economic evaluation: the QALY and utilities.","volume":"96","author":"Whitehead","year":"2010","journal-title":"Br Med Bull"},{"key":"2022092122004656100_CIT0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2337\/dc12-0759","article-title":"Cost-effectiveness of hepatitis B vaccination in adults with diagnosed diabetes.","volume":"36","author":"Hoerger","year":"2013","journal-title":"Diabetes Care"},{"key":"2022092122004656100_CIT0041","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.amepre.2008.03.028","article-title":"Economic evaluation of delivering hepatitis B vaccine to injection drug users.","volume":"35","author":"Hu","year":"2008","journal-title":"Am J Prev Med"},{"key":"2022092122004656100_CIT0042","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1177\/003335490812300412","article-title":"Economic benefits of hepatitis B vaccination at sexually transmitted disease clinics in the U.S.","volume":"123","author":"Miriti","year":"2008","journal-title":"Public Health Rep"},{"key":"2022092122004656100_CIT0043","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.amepre.2006.01.017","article-title":"Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites.","volume":"30","author":"Kim","year":"2006","journal-title":"Am J Prev Med"},{"key":"2022092122004656100_CIT0044","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.vaccine.2018.11.056","article-title":"Cost-effectiveness of adult vaccinations: a systematic review.","volume":"37","author":"Leidner","year":"2019","journal-title":"Vaccine"},{"key":"2022092122004656100_CIT0045","doi-asserted-by":"crossref","first-page":"47","DOI":"10.15585\/mmwr.mm6503a2","article-title":"Increases in acute hepatitis B virus infections - Kentucky, Tennessee, and West Virginia, 2006\u20132013.","volume":"65","author":"Harris","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022092122004656100_CIT0046","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1465-3362.2011.00291.x","article-title":"The prescription drug epidemic in the United States: a perfect storm.","volume":"30","author":"Maxwell","year":"2011","journal-title":"Drug Alcohol Rev"},{"key":"2022092122004656100_CIT0047","first-page":"453","article-title":"Increases in hepatitis C virus infection related to injection drug use among persons aged \u226430 years\u2014Kentucky, Tennessee, Virginia, and West Virginia, 2006\u20132012.","volume":"64","author":"Zibbell","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022092122004656100_CIT0048","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jval.2012.06.011","article-title":"Dynamic transmission modeling: a report of the ISPOR-SMDM modeling good research practices task force-5.","volume":"15","author":"Pitman","year":"2012","journal-title":"Value Health"},{"key":"2022092122004656100_CIT0049","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost-effectiveness of interventions: alternative approaches.","volume":"93","author":"Marseille","year":"2014","journal-title":"Bull World Health Organ"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiac088\/43255492\/jiac088.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/6\/1041\/45966807\/jiac088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/6\/1041\/45966807\/jiac088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T18:04:47Z","timestamp":1663783487000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/226\/6\/1041\/6545195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3,9]]},"published-print":{"date-parts":[[2022,9,21]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiac088","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,15]]},"published":{"date-parts":[[2022,3,9]]}}}